Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
about
Therapy for haemophilia: recent advances and goals for the future.Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Application of current knowledge to the management of bleeding events during immune tolerance induction.An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience.Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.International recommendations on the diagnosis and treatment of patients with acquired hemophilia ASequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.Acquired hemophilia: a rare but life-threatening potential cause of bleeding in the intensive care unit.Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceSequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience.Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitorsModeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors.Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography.Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.How I manage patients with inherited haemophilia A and B and factor inhibitors.
P2860
Q36066048-3C79FF01-5B8B-4618-B83E-8B1CA4CBA332Q36291064-FA8BF330-2A09-4F3B-A820-D2C6AFD30A69Q36480548-AE17E6DE-6A8E-4DE0-8F2D-E3B2E774EA85Q36643874-C614B7D8-01A7-4A33-98A1-250A9C13FBEFQ36661836-1CD2E178-015B-4174-B339-ED33B898807DQ36819965-00FA9BA6-3FFF-43F8-A1AA-D29A6CFA83BAQ36945945-A270AED7-E3D0-45A6-9654-7955382D46F2Q36985329-688D80EF-75D0-498A-89AF-556946848723Q37146064-AF936681-85A0-4625-B5DF-FA3C84BF5485Q37842692-391EFB1C-DE67-4F00-A6F0-5BB74044DC11Q37882559-7110F616-C913-4BFF-B1A1-BA2E5D9679A8Q37927122-50780665-F099-471D-BAAF-B81F195EBE69Q38101041-A66EB8EF-2493-4909-971D-E90368958269Q38182105-9B22E553-A618-4819-B63D-8F36F6E688E3Q40539842-FDF0BDC7-10F6-42F5-80D8-9B0F2B58D86CQ42776949-CBEA48D2-D188-4265-B26A-26400FA1CB98Q44211358-18175424-2851-4851-A6D0-FE3B682B8D2DQ45851000-56A56CC8-D98F-4D0E-AA13-834F5D0613DBQ45859169-94A2A1DB-4F41-4E36-B713-26D59CD0BA10Q45863543-79F77641-4ED1-49FB-ACA3-FC045E22889EQ45866930-BDE1C77E-38EC-49D8-A956-30EAD9ED02E7Q45868043-74789000-71F5-441E-90C6-9535C49E52F4Q45874410-9ABA7174-61D4-4956-8414-98811D99A9B1Q45883290-BE111496-32C2-4696-B69E-9A1CE90EB06FQ45886119-3C01A889-8FF7-4E2D-88C3-798B58B9B194Q48359988-F3554289-0375-49A5-93D9-2A1613EE9560
P2860
Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Sequential therapy with activa ...... re haemophilia and inhibitors.
@ast
Sequential therapy with activa ...... re haemophilia and inhibitors.
@en
type
label
Sequential therapy with activa ...... re haemophilia and inhibitors.
@ast
Sequential therapy with activa ...... re haemophilia and inhibitors.
@en
prefLabel
Sequential therapy with activa ...... re haemophilia and inhibitors.
@ast
Sequential therapy with activa ...... re haemophilia and inhibitors.
@en
P2860
P1433
P1476
Sequential therapy with activa ...... re haemophilia and inhibitors.
@en
P2093
D J Nugent
J Schneiderman
P2860
P304
P356
10.1111/J.1365-2516.2004.00912.X
P50
P577
2004-07-01T00:00:00Z